Back |
home / stock / fgen / fgen message board
Subject | By | Source | When |
---|---|---|---|
Phase 2 Data for Investigational Orally Active HIF-PHI | LongRun8 | investorshub | 10/23/2015 2:42:57 AM |
2Q15 CC notes: #msg-116201630. | DewDiligence | investorshub | 08/15/2015 2:08:43 AM |
Still holding. Will hold for 30+ | SealTheDeal | investorshub | 08/15/2015 2:04:45 AM |
Still holding 18's. Think $25 this week | SealTheDeal | investorshub | 07/13/2015 4:47:55 PM |
Parabolic move today | SealTheDeal | investorshub | 06/23/2015 2:20:44 PM |
$FGEN DD Notes ~ http://www.ddnotesmaker.com/$FGEN | stocktrademan | investorshub | 12/17/2014 3:38:26 PM |
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...